CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 12 miesięcy do 21 lat
- •Potwierdzony nowotwór w badaniu histologicznym
- •Nowotwór powrócił po leczeniu lub nie reaguje na leczenie
- •Może być nowotwór mózgu lub przerzuty do mózgu
- •Nowotwór można zmierzyć lub ocenić w badaniach
- •Stan ogólny dziecka pozwala na uczestnictwo w badaniu
- •Wystarczająco długi czas od poprzedniego leczenia przeciwnowotworowego
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Months
- Maximum age
- 21 Years
- Last updated (source)
- September 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (35)
Children's Hospital of Alabama
Birmingham, United States
Phoenix Childrens Hospital
Phoenix, United States
Children's Hospital Los Angeles
Los Angeles, United States
Children's Hospital of Orange County
Orange, United States
UCSF Medical Center-Mission Bay
San Francisco, United States
Children's Hospital Colorado
Aurora, United States
Children's National Medical Center
Washington D.C., United States
Johns Hopkins All Children's Hospital
St. Petersburg, United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, United States
Lurie Children's Hospital-Chicago
Chicago, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
Riley Hospital for Children
Indianapolis, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Dana-Farber Cancer Institute
Boston, United States
C S Mott Children's Hospital
Ann Arbor, United States
University of Minnesota/Masonic Cancer Center
Minneapolis, United States
Children's Mercy Hospitals and Clinics
Kansas City, United States
Washington University School of Medicine
St Louis, United States
Roswell Park Cancer Institute
Buffalo, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
New York Medical College
Valhalla, United States
Duke University Medical Center
Durham, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Oregon Health and Science University
Portland, United States
Children's Hospital of Philadelphia
Philadelphia, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, United States
Saint Jude Children's Research Hospital
Memphis, United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, United States
Cook Children's Medical Center
Fort Worth, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, United States
Primary Children's Hospital
Salt Lake City, United States
Seattle Children's Hospital
Seattle, United States
Children's Hospital of Wisconsin
Milwaukee, United States
Sydney Children's Hospital
Randwick, Australia
Trial contact
Site Public Contact
Girish Dhall
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alok K. Kothari
PRINCIPAL_INVESTIGATOR
Site Public Contact
Fariba Navid
PRINCIPAL_INVESTIGATOR
Site Public Contact
Elyssa M. Rubin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kieuhoa T. Vo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Margaret E. Macy
PRINCIPAL_INVESTIGATOR
Site Public Contact
AeRang Kim
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jonathan L. Metts
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jason R. Fangusaro
PRINCIPAL_INVESTIGATOR
Site Public Contact
Elizabeth A. Sokol
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ami V. Desai
PRINCIPAL_INVESTIGATOR
Site Public Contact
Brian D. Weiss
PRINCIPAL_INVESTIGATOR
Site Public Contact
Christine A. Pratilas
PRINCIPAL_INVESTIGATOR
Site Public Contact
Steven G. DuBois
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rajen Mody
PRINCIPAL_INVESTIGATOR
Site Public Contact
Robin L. Williams
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kevin F. Ginn
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shalini Shenoy
PRINCIPAL_INVESTIGATOR
Site Public Contact
Clare J. Twist
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nobuko Hijiya
PRINCIPAL_INVESTIGATOR
Site Public Contact
Julia L. Glade Bender
PRINCIPAL_INVESTIGATOR
Site Public Contact
Mitchell S. Cairo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jessica M. Sun
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joseph G. Pressey
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bill H. Chang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Theodore W. Laetsch
PRINCIPAL_INVESTIGATOR
Site Public Contact
Andrew Bukowinski
PRINCIPAL_INVESTIGATOR
Site Public Contact
Dana Tlais
PRINCIPAL_INVESTIGATOR
Site Public Contact
Laura J. Klesse
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sibo Zhao
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jennifer H. Foster
PRINCIPAL_INVESTIGATOR
Site Public Contact
Matthew Dietz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sarah Rumler
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.